LSE:BP.
LSE:BP.Oil and Gas

Is BP Still a Value Opportunity After its 107.7% Surge and Strategy Shift?

If you are wondering whether BP is still a value opportunity after its big run over the last few years, or if most of the upside is already priced in, this article will walk you through that question step by step. Despite climbing 107.7% over the last 5 years and 17.5% over the past year, the stock has cooled recently, with a 9.0% gain year to date but short-term dips of 3.0% over 7 days and 4.7% over 30 days that may be catching value-focused investors' attention. Those moves have played...
LSE:AZN
LSE:AZNPharmaceuticals

AstraZeneca (LSE:AZN): Revisiting Valuation After a Strong Multi‑Year Share Price Run

AstraZeneca (LSE:AZN) has been quietly reshaping its growth story, and the latest trading action reflects investors weighing that shift against a share price that is already up about 31% over the past year. See our latest analysis for AstraZeneca. That momentum has cooled a little in recent weeks, with the 30 day share price return slightly negative, even as a strong 90 day share price return and robust five year total shareholder return suggest investors are still rewarding AstraZeneca’s...